Previous Article
Prometic to initiate PBI-4050 pivotal phase 3 clinical trial in Alström Syndrome
Prometic to initiate PBI-4050 pivotal phase 3 clinical trial in Alström Syndrome

The protocol for the Phase 3 clinical trial will be designed to meet expectations from both the U.S and EU ...

Next Article
Prometic to host key opinion leader meeting on PBI-4050, a novel treatment for Alström Syndrome
Prometic to host key opinion leader meeting on PBI-4050, a novel treatment for Alström Syndrome

Key Opinion Leader meeting, Friday, September 7th in New York City, on a novel treatment for Alström Syndro...